Antibody-drug conjugates: Principles and opportunities

Area of Science:

• Oncology
• Immunology
• Pharmacology

Background:

• Antibody-drug conjugates (ADCs) represent a promising class of cancer therapeutics.
• ADCs leverage monoclonal antibodies for targeted delivery of potent cytotoxic payloads to tumor cells.
• This targeted approach aims to improve efficacy and reduce systemic toxicity compared to traditional chemotherapy.

Purpose of the Study:

• To provide an overview of antibody specificity and ADC structure.
• To discuss the mechanisms of action and resistance development in ADCs.
• To explore strategies for enhancing ADC efficacy and overcoming resistance.

Main Methods:

• Literature review and synthesis of current research on ADCs.
• Analysis of ADC mechanisms, resistance pathways, and therapeutic advancements.
• Exploration of future perspectives in ADC development for cancer treatment.

Main Results:

• ADCs combine antibody specificity with cytotoxic payloads for targeted tumor cell killing.
• Advances in target identification, payloads, and linkers have expanded ADC therapeutic potential.
• Understanding resistance mechanisms is crucial for optimizing ADC efficacy.

Conclusions:

• ADCs offer a targeted approach to cancer treatment with reduced side effects.
• Continued research into novel targets, payloads, and overcoming resistance is vital for advancing ADC therapy.
• ADCs hold significant promise for improving outcomes in cancer treatment.